Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28563351 | 0.74 | KMT2A (0.50) | LMNANPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL16489239 | 0.74 | KMT2A (0.45) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL16489226 | 0.71 | KMT2A (0.45) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1753018 | 0.69 | MEN1 (0.51) | LMNANPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL19902755 | 0.69 | KMT2A (0.43) | LMNANPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL16489223 | 0.69 | KMT2A (0.58) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5666204 | 0.69 | FADS1 (0.67) | LMNANPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL13962554 | 0.68 | KMT2A (0.59) | LMNANPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL4122903 | 0.68 | NPC1 (0.71) | LMNANPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL4118553 | 0.68 | NPC1 (0.69) | LMNANPC1RAB9ASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625912-B2 | 2-Phenylpyrimidinone compounds; anticarcinogenic agents can be synergistically combined with one or more active ingredients such as paclitaxel or trastuzumab; side effect reduction | MERCK & CO. INC (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625912-B2 | 2-Phenylpyrimidinone compounds; anticarcinogenic agents can be synergistically combined with one or more active ingredients such as paclitaxel or trastuzumab; side effect reduction | MERCK & CO. INC (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625912-B2 | 2-Phenylpyrimidinone compounds; anticarcinogenic agents can be synergistically combined with one or more active ingredients such as paclitaxel or trastuzumab; side effect reduction | MERCK & CO. INC (US) | 2009-12-01 | — | — | US | disclosed |
| US-20070129356-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2007-06-07 | — | — | US | disclosed |
| US-20070129356-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2007-06-07 | — | — | US | disclosed |
| US-20070129356-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2007-06-07 | — | — | US | disclosed |
| EP-1697331-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005060654-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129356-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF18B | LMNA 2852/4885NPC1 1332/4885RAB9A 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.